Antibiotic Resistance: Current Practices and Strategies to Overcome this Growing Threat
Biopharm Reports has carried two comprehensive market studies, covering bacterial molecular diagnostics and antibiotic resistance. These studies involved the participation of 1072 experienced researchers, clinicians and laboratory end-users and profiled current practices, developments, trends and plans over the next three years, as well as growth and opportunities across key sectors of these markets. These findings provide a wealth of market information on the current and evolving markets for bacterial molecular diagnostics and antibiotic resistance.
BACTERIAL MOLECULAR DIAGNOSTICS
This study profiled 420 experienced clinicians and research scientists and investigated current practices, developments, trends and future plans over the next three years, as well as growth, shrinkage and opportunities across key areas of this market. Its findings provide suppliers with market information on the current and evolving use of bacterial molecular diagnostics. The study investigated 45 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on the current and evolving use of bacterial molecular diagnostics and assist companies selling into these markets to respond to laboratory users’ current needs and their future plans.
Market studies carried out by Biopharm Reports are designed to assist laboratory suppliers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user needs, our studies assist suppliers to sell into these markets, and support innovation, development and strategic planning.
ANTIBIOTIC RESISTANCE
Market findings from this study are based on 'real world' laboratory data, provided by research scientists and clinicians who work routinely on the challenges posed by antibiotic resistance.
This study investigated 117 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on current and developing activities to combat antibiotic resistance and assist companies selling into these markets to respond to laboratory users’ current needs and their future plans.
Biopharm Reports specialises in carrying out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years. The associated report provides a competitive market analysis of current practices and future developments across 25 key areas relating to antibiotic resistance. Examples include:
BACTERIAL MOLECULAR DIAGNOSTICS
This study profiled 420 experienced clinicians and research scientists and investigated current practices, developments, trends and future plans over the next three years, as well as growth, shrinkage and opportunities across key areas of this market. Its findings provide suppliers with market information on the current and evolving use of bacterial molecular diagnostics. The study investigated 45 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on the current and evolving use of bacterial molecular diagnostics and assist companies selling into these markets to respond to laboratory users’ current needs and their future plans.
Market studies carried out by Biopharm Reports are designed to assist laboratory suppliers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user needs, our studies assist suppliers to sell into these markets, and support innovation, development and strategic planning.
ANTIBIOTIC RESISTANCE
Market findings from this study are based on 'real world' laboratory data, provided by research scientists and clinicians who work routinely on the challenges posed by antibiotic resistance.
This study investigated 117 market areas covering current activities, recent developments and trends, anticipated future growth, shrinkage and opportunities. Its findings provide market information on current and developing activities to combat antibiotic resistance and assist companies selling into these markets to respond to laboratory users’ current needs and their future plans.
Biopharm Reports specialises in carrying out market studies of techniques and applications used in life science laboratories and clinics. All our studies involve the participation of scientists and clinicians and investigate in-depth, key areas of their current use of specialised laboratory techniques, and their plans for using these techniques over the next three years. The associated report provides a competitive market analysis of current practices and future developments across 25 key areas relating to antibiotic resistance. Examples include:
- Diagnostics: Therapeutic areas, top Gram positives, Gram negatives and other pathogens; current and future development of companion diagnostics, tests to distinguish between bacterial and viral infections, the identification of causal bacterial pathogens, bacterial identification methods, preferred tests and instrumentation, preferred suppliers, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives and barriers to success.
- Clinical: Therapeutic areas, top infection types, the major Gram positives, Gram negatives and other pathogens; distinguishing bacterial and viral infections, test costs and test times per patient, the identification of causal bacterial, preferred methods and suppliers, the identification of antibiotic resistance genes, integrated and antimicrobial stewardship programmes, requirements for innovation, new initiatives, barriers to success and future plans in these areas
- Suppliers: Who are the major company suppliers in the ‘antibiotic resistance’ market and who do diagnosticians and clinicians plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted in three years from now.
- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the ‘antibiotic resistance’ market, in each of the 'Diagnostics’, ‘Clinical’ and ‘Laboratory’ areas indicated below.
1. GENERAL
1.1 Study description
1.2 Participants
1.3 Countries
1.4 organisations
2. CLINICAL
2.1 Top Therapeutic Areas
2.2 Top Infection Types
2.3 Differentiating Bacterial and Viral Infections
2.3.1 Current patients
2.3.2 Preferred distinguishing tests
2.3.3 Suppliers and instrumentation
2.3.4 Test costs per patient
2.3.5 Test time
2.3.6 Future distinction between bacterial and viral infections
2.3.7 Future patients
2.3.8 Future tests and instrumentation
2.3.9 Future preferred suppliers
2.4 Causal Bacteria
2.4.1 Identification methods
2.4.2 Current patients
2.4.3 Laboratory identification methods
2.4.4 Preferred tests and instrumentation
2.4.5 Preferred suppliers
2.4.6 Test costs per patient
2.4.7 Test time
2.4.8 Future identification of causal bacterial types
2.4.9 Future patients
2.4.10 Future bacterial identification methods
2.4.11 Tests and instrumentation
2.4.12 Preferred suppliers
2.5 Antibiotic Resistance Genes
2.5.1 Current patients
2.5.2 Preferred tests and instrumentation
2.5.3 Preferred suppliers
2.5.4 Testing costs
2.5.5 Test time
2.5.6 Future identification of resistance genes
2.5.7 Future patients
2.5.8 Antibiotic resistance gene tests and instrumentation
2.5.9 Future suppliers
2.6 Integrated Programmes
2.6.1 Current programmes
2.6.2 Names and locations
2.6.3 Future programmes
2.6.4 Names and locations
2.7 Antimicrobial stewardship programmes
2.7.1 Current programmes
2.7.2 Names and locations
2.7.3 Future programmes
2.7.4 Names and locations
2.7.5 Future antimicrobial stewardship programmes
2.7.6 Name and location
2.8 Gram negative bacteria
2.9 Gram positive bacteria
2.10 Other bacteria
2.11 Antibiotics against Gram negative bacteria
2.12 Antibiotics against Gram positive bacteria
2.13 Antibiotics against other bacteria
2.14 Treatment costs
2.15 Single antibiotics or combinations
2.16 Innovation
2.17 Barriers
2.18 Initiatives
3. LABORATORY
3.1 Purpose
3.2 Top three therapeutic areas
3.3 Antibiotic source
3.4 Gram negative bacteria
3.5 Gram positive bacteria
3.6 Other bacteria
3.7 Companion diagnostics
3.8 Current Identification methods
3.8.1 Preferred current products and suppliers
3.9 Future identification methods
3.9.1 Preferred products and supplier
3.10 Antibiotics against Gram negative bacteria
3.11 Antibiotics against Gram positive bacteria
3.12 Antibiotics against other bacteria
3.13 Novel antibiotic combinations
3.14 Single antibiotics or combinations
3.15 Integrated programmes
3.15.1 Current programmes
3.15.2 Names and locations
3.15.3 Future programmes
3.15.4 Names and locations
3.16 Current programme
3.17 Future integrated programme
3.18 Name and location
3.19 Antimicrobial stewardship programmes
3.19.1 Current programmes
3.19.2 Names and locations
3.19.3 Future programmes
3.19.4 Names and locations
3.20 Innovation
3.21 Barriers
3.22 Initiatives
4. DIAGNOSTICS
4.1 Therapeutic areas
4.2 Source of antibiotics
4.3 Gram negative bacteria
4.4 Gram positive bacteria
4.5 Other bacteria
4.6 Companion diagnostics
4.7 Bacterial and viral infections
4.8 Future tests for distinguishing bacterial and viral infections
4.9 Identifying causal bacteria
4.10 laboratory identification methods
4.10.1 Preferred products and suppliers
4.11 Future identification of causal bacterial types
4.11.1 Preferred products and suppliers
4.12 Integrated programmes
4.12.1 Current programmes
4.12.2 Names and locations
4.12.3 Future programmes
4.12.4 Names and locations
4.13 Antimicrobial stewardship programmes
4.13.1 Current programmes
4.13.2 Names and locations
4.13.3 Future programmes
4.13.4 Names and locations
4.14 Innovation
4.15 Barriers
4.16 Initiatives
BACTERIAL MOLECULAR DIAGNOSTICS
1. INTRODUCTION
1.1. Market Questions
1.2. Discussion
2. PARTICIPANTS
2.1 Global Regions
2.2 Countries
2.3 Job Title
2.4 Experience
2.5 Organisation Type
2.6 Field
2.7 Purpose
2.8 Role
2.9 Main Activity
2.10 Discussion
3. ASSOCIATED THERAPEUTIC AREAS
3.1. Associated Therapeutic Areas
3.2 Market Questions
3.3 Other Therapeutic Areas
3.4. Discussion
4. BACTERIA
4.1 Market Questions
4.2 Current Gram Negative Bacteria
4.3 Future Gram Negative Bacteria
4.4 Current Gram Positive Bacteria
4.5 Future Gram Positive Bacteria
4.6 Current Other Bacteria
4.7 Future Other Bacteria
4.8 Discussion
5 MAIN BACTERIAL TESTS
5.1. Main Bacterial Tests
5.2 Market Questions
5.3 Current Bacterial Tests
5.4 Other Current Bacterial Tests
5.5 Future Bacterial Tests
5.6 Other Future Bacterial Tests
5.7 Discussion
6 SAMPLES
6.1 Samples
6.2 Market Question
6.3. Samples
6.4. Discussion
7 BACTERIAL MOLECULAR TECHNIQUES
7.1 Bacterial Molecular Techniques
7.2 Market Questions
7.3 Current Molecular Techniques
7.4 Other Current Molecular Techniques
7.5 Future Molecular Techniques
7.6 Other Future Molecular Techniques
7.7 Discussion
8 MAIN BACTERIAL TESTED
8.1 Main Bacteria Tested
8.2 Market Questions
8.3 Current Gram Negative Bacteria
8.4 Future Gram Negative Bacteria
8.5 Current Main Gram Positive Bacteria
8.6 Future Gram Positive Bacteria
8.7. Current Other Bacteria
8.8 Future Other Bacteria
8.9 Discussion
9 BACTERIA TESTED SIMULTANEOUSLY
9.1 Bacteria Tested Simultaneously
9.2 Market Question
9.3 Current Bacteria Tested Simultaneously
9.4 Future Bacteria Tested Simultaneously
9.5 Discussion
10 MULTIPLEX METHODS
10.1 Multiplex Methods
10.2 Market Questions
10.3 Current Multiplex Methods
10.4 Future Multiplex Methods
10.5 Discussion
11 BACTERIAL MOLECULAR DIAGNOSTIC TRENDS
11.1 Bacterial Molecular Diagnostic Trends
11.2 Market Questions
11.3 Recent Trends
11.4 Future Trends
11.5 Discussion
12 APPLICATIONS
12.1 Applications
12.2 Market Questions
12.3 Current Main Applications
12.4 Other Current Applications
12.5 Future Applications
12.6 Other Future Applications
12.7 Discussion
13 SUPPLIERS
13.1 Suppliers
13.2 Market Questions
13.3 Current Suppliers
13.4 Other Current Suppliers
13.5 Future Suppliers
13.6 Other Future Suppliers
13.7 Discussion
14 ADVANTAGES AND DISADVANTAGES
14.1 Advantages and Disadvantages
14.2 Market Questions
14.3 Advantages
14.4 Other Advantages
14.5 Disadvantages
14.6 Other Disadvantages
14.7 Discussion
15 FUTURE IMPROVEMENTS
15.1 Future Improvements
15.2 Market Questions
15.3 Future Improvements
15.4 Other Future Improvements
15.5 Discussion
16 TECHNIQUE REPLACEMENT
16.1 Technique Replacement
16.2 Market Questions
16.3 Technique Replacement
16.4 Other Technique Replacement
16.5 Discussion
17 AUTOMATION
17.1 Automation
17.2 Market Questions
17.3 Current Automation
17.4 Preferred Automation Suppliers
17.5 Discussion
18 MOST TESTED BACTERIA
18.1 Most Tested Bacteria
18.2 Market Questions
18.3 Most Tested Bacteria
18.4 Costs
18.5 Budget
18.6 Preferred Suppliers
18.7 Other Preferred Suppliers
18.8 Discussion
19 DISCUSSION
1.1 Study description
1.2 Participants
1.3 Countries
1.4 organisations
2. CLINICAL
2.1 Top Therapeutic Areas
2.2 Top Infection Types
2.3 Differentiating Bacterial and Viral Infections
2.3.1 Current patients
2.3.2 Preferred distinguishing tests
2.3.3 Suppliers and instrumentation
2.3.4 Test costs per patient
2.3.5 Test time
2.3.6 Future distinction between bacterial and viral infections
2.3.7 Future patients
2.3.8 Future tests and instrumentation
2.3.9 Future preferred suppliers
2.4 Causal Bacteria
2.4.1 Identification methods
2.4.2 Current patients
2.4.3 Laboratory identification methods
2.4.4 Preferred tests and instrumentation
2.4.5 Preferred suppliers
2.4.6 Test costs per patient
2.4.7 Test time
2.4.8 Future identification of causal bacterial types
2.4.9 Future patients
2.4.10 Future bacterial identification methods
2.4.11 Tests and instrumentation
2.4.12 Preferred suppliers
2.5 Antibiotic Resistance Genes
2.5.1 Current patients
2.5.2 Preferred tests and instrumentation
2.5.3 Preferred suppliers
2.5.4 Testing costs
2.5.5 Test time
2.5.6 Future identification of resistance genes
2.5.7 Future patients
2.5.8 Antibiotic resistance gene tests and instrumentation
2.5.9 Future suppliers
2.6 Integrated Programmes
2.6.1 Current programmes
2.6.2 Names and locations
2.6.3 Future programmes
2.6.4 Names and locations
2.7 Antimicrobial stewardship programmes
2.7.1 Current programmes
2.7.2 Names and locations
2.7.3 Future programmes
2.7.4 Names and locations
2.7.5 Future antimicrobial stewardship programmes
2.7.6 Name and location
2.8 Gram negative bacteria
2.9 Gram positive bacteria
2.10 Other bacteria
2.11 Antibiotics against Gram negative bacteria
2.12 Antibiotics against Gram positive bacteria
2.13 Antibiotics against other bacteria
2.14 Treatment costs
2.15 Single antibiotics or combinations
2.16 Innovation
2.17 Barriers
2.18 Initiatives
3. LABORATORY
3.1 Purpose
3.2 Top three therapeutic areas
3.3 Antibiotic source
3.4 Gram negative bacteria
3.5 Gram positive bacteria
3.6 Other bacteria
3.7 Companion diagnostics
3.8 Current Identification methods
3.8.1 Preferred current products and suppliers
3.9 Future identification methods
3.9.1 Preferred products and supplier
3.10 Antibiotics against Gram negative bacteria
3.11 Antibiotics against Gram positive bacteria
3.12 Antibiotics against other bacteria
3.13 Novel antibiotic combinations
3.14 Single antibiotics or combinations
3.15 Integrated programmes
3.15.1 Current programmes
3.15.2 Names and locations
3.15.3 Future programmes
3.15.4 Names and locations
3.16 Current programme
3.17 Future integrated programme
3.18 Name and location
3.19 Antimicrobial stewardship programmes
3.19.1 Current programmes
3.19.2 Names and locations
3.19.3 Future programmes
3.19.4 Names and locations
3.20 Innovation
3.21 Barriers
3.22 Initiatives
4. DIAGNOSTICS
4.1 Therapeutic areas
4.2 Source of antibiotics
4.3 Gram negative bacteria
4.4 Gram positive bacteria
4.5 Other bacteria
4.6 Companion diagnostics
4.7 Bacterial and viral infections
4.8 Future tests for distinguishing bacterial and viral infections
4.9 Identifying causal bacteria
4.10 laboratory identification methods
4.10.1 Preferred products and suppliers
4.11 Future identification of causal bacterial types
4.11.1 Preferred products and suppliers
4.12 Integrated programmes
4.12.1 Current programmes
4.12.2 Names and locations
4.12.3 Future programmes
4.12.4 Names and locations
4.13 Antimicrobial stewardship programmes
4.13.1 Current programmes
4.13.2 Names and locations
4.13.3 Future programmes
4.13.4 Names and locations
4.14 Innovation
4.15 Barriers
4.16 Initiatives
BACTERIAL MOLECULAR DIAGNOSTICS
1. INTRODUCTION
1.1. Market Questions
1.2. Discussion
2. PARTICIPANTS
2.1 Global Regions
2.2 Countries
2.3 Job Title
2.4 Experience
2.5 Organisation Type
2.6 Field
2.7 Purpose
2.8 Role
2.9 Main Activity
2.10 Discussion
3. ASSOCIATED THERAPEUTIC AREAS
3.1. Associated Therapeutic Areas
3.2 Market Questions
3.3 Other Therapeutic Areas
3.4. Discussion
4. BACTERIA
4.1 Market Questions
4.2 Current Gram Negative Bacteria
4.3 Future Gram Negative Bacteria
4.4 Current Gram Positive Bacteria
4.5 Future Gram Positive Bacteria
4.6 Current Other Bacteria
4.7 Future Other Bacteria
4.8 Discussion
5 MAIN BACTERIAL TESTS
5.1. Main Bacterial Tests
5.2 Market Questions
5.3 Current Bacterial Tests
5.4 Other Current Bacterial Tests
5.5 Future Bacterial Tests
5.6 Other Future Bacterial Tests
5.7 Discussion
6 SAMPLES
6.1 Samples
6.2 Market Question
6.3. Samples
6.4. Discussion
7 BACTERIAL MOLECULAR TECHNIQUES
7.1 Bacterial Molecular Techniques
7.2 Market Questions
7.3 Current Molecular Techniques
7.4 Other Current Molecular Techniques
7.5 Future Molecular Techniques
7.6 Other Future Molecular Techniques
7.7 Discussion
8 MAIN BACTERIAL TESTED
8.1 Main Bacteria Tested
8.2 Market Questions
8.3 Current Gram Negative Bacteria
8.4 Future Gram Negative Bacteria
8.5 Current Main Gram Positive Bacteria
8.6 Future Gram Positive Bacteria
8.7. Current Other Bacteria
8.8 Future Other Bacteria
8.9 Discussion
9 BACTERIA TESTED SIMULTANEOUSLY
9.1 Bacteria Tested Simultaneously
9.2 Market Question
9.3 Current Bacteria Tested Simultaneously
9.4 Future Bacteria Tested Simultaneously
9.5 Discussion
10 MULTIPLEX METHODS
10.1 Multiplex Methods
10.2 Market Questions
10.3 Current Multiplex Methods
10.4 Future Multiplex Methods
10.5 Discussion
11 BACTERIAL MOLECULAR DIAGNOSTIC TRENDS
11.1 Bacterial Molecular Diagnostic Trends
11.2 Market Questions
11.3 Recent Trends
11.4 Future Trends
11.5 Discussion
12 APPLICATIONS
12.1 Applications
12.2 Market Questions
12.3 Current Main Applications
12.4 Other Current Applications
12.5 Future Applications
12.6 Other Future Applications
12.7 Discussion
13 SUPPLIERS
13.1 Suppliers
13.2 Market Questions
13.3 Current Suppliers
13.4 Other Current Suppliers
13.5 Future Suppliers
13.6 Other Future Suppliers
13.7 Discussion
14 ADVANTAGES AND DISADVANTAGES
14.1 Advantages and Disadvantages
14.2 Market Questions
14.3 Advantages
14.4 Other Advantages
14.5 Disadvantages
14.6 Other Disadvantages
14.7 Discussion
15 FUTURE IMPROVEMENTS
15.1 Future Improvements
15.2 Market Questions
15.3 Future Improvements
15.4 Other Future Improvements
15.5 Discussion
16 TECHNIQUE REPLACEMENT
16.1 Technique Replacement
16.2 Market Questions
16.3 Technique Replacement
16.4 Other Technique Replacement
16.5 Discussion
17 AUTOMATION
17.1 Automation
17.2 Market Questions
17.3 Current Automation
17.4 Preferred Automation Suppliers
17.5 Discussion
18 MOST TESTED BACTERIA
18.1 Most Tested Bacteria
18.2 Market Questions
18.3 Most Tested Bacteria
18.4 Costs
18.5 Budget
18.6 Preferred Suppliers
18.7 Other Preferred Suppliers
18.8 Discussion
19 DISCUSSION
FIGURES
Figure 2.1. Global regions of participants in BMD
Figure 2.2. Countries of participants in BMD
Figure 2.3. Job titles of participants in BMD
Figure 2.4. Bacterial diagnostics experience of participants in BMD
Figure 2.5. Organisations of participants in BMD
Figure 2.6. Fields of participants in BMD
Figure 2.7. Purpose of Bacterial diagnostics activities of participants in BMD4
Figure 2.8. Role of participants in BMD
Figure 2.9. Main activity of participants in BMD
Figure 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics
Figure 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 5.2. Main types of bacterial tests currently used, indicated by participants in BMD
Figure 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD
Figure 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD
Figure 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD
Figure 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD
Figure 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.4. Main Gram negative bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD
Figure 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD
Figure 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD
Figure 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD
Figure 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD
Figure 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD
Figure 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BM
Figure 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD
Figure 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD
Figure 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD
Figure 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Figure 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Figure 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD
Figure 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD
Figure 17.2. Percentage of end-users bacterial molecular diagnostics that are automated, indicated by participants in BMD
Figure 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD
Figure 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD
Figure 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
Figure 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
Figure 2.1. Global regions of participants in BMD
Figure 2.2. Countries of participants in BMD
Figure 2.3. Job titles of participants in BMD
Figure 2.4. Bacterial diagnostics experience of participants in BMD
Figure 2.5. Organisations of participants in BMD
Figure 2.6. Fields of participants in BMD
Figure 2.7. Purpose of Bacterial diagnostics activities of participants in BMD4
Figure 2.8. Role of participants in BMD
Figure 2.9. Main activity of participants in BMD
Figure 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics
Figure 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD
Figure 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Figure 5.2. Main types of bacterial tests currently used, indicated by participants in BMD
Figure 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD
Figure 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD
Figure 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD
Figure 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD
Figure 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.4. Main Gram negative bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Figure 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Figure 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD
Figure 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD
Figure 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD
Figure 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD
Figure 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD
Figure 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD
Figure 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BM
Figure 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD
Figure 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD
Figure 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD
Figure 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Figure 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Figure 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD
Figure 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD
Figure 17.2. Percentage of end-users bacterial molecular diagnostics that are automated, indicated by participants in BMD
Figure 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD
Figure 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD
Figure 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
Figure 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
TABLES
Table 2.1. Global regions of participants in BMD
Table 2.2. Countries of participants in BMD
Table 2.3. Job titles of participants in BMD
Table 2.4. Bacterial diagnostics experience of participants in BMD
Table 2.5. Organisations of participants in BMD
Table 2.6. Fields of participants in BMD
Table 2.7. Purpose of Bacterial diagnostics activities of participants in BMD
Table 2.8. Pole of participants in BMD
Table 2.9. Main activity of participants in BMD
Table 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics
Table 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD
Table 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD
Table 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD
Table 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 5.2. Main types of bacterial tests currently used, indicated by participants in BMD
Table 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD
Table 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD
Table 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD
Table 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD
Table 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.4. Main Gram negative bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD
Table 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD
Table 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD
Table 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD
Table 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD
Table 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD
Table 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BMD
Table 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD
Table 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD
Table 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD
Table 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Table 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Table 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD
Table 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD
Table 17.2. Percentage of end-users bacterial molecular diagnostics that are automated, indicated by participants in BMD
Table 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD
Table 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD
Table 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests indicated referred to, indicated by participants in BMD
Table 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
Table 2.1. Global regions of participants in BMD
Table 2.2. Countries of participants in BMD
Table 2.3. Job titles of participants in BMD
Table 2.4. Bacterial diagnostics experience of participants in BMD
Table 2.5. Organisations of participants in BMD
Table 2.6. Fields of participants in BMD
Table 2.7. Purpose of Bacterial diagnostics activities of participants in BMD
Table 2.8. Pole of participants in BMD
Table 2.9. Main activity of participants in BMD
Table 3.2. Associated therapeutic areas participants work in, relating to bacterial molecular diagnostics
Table 4.2. Main Gram negative bacteria currently treated or worked with, indicated by participants in BMD
Table 4.4. main Gram negative bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 4.6. Main Gram positive bacteria currently treated or worked with, indicated by participants in BMD
Table 4.8. Main Gram positive bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 4.10. Main other bacteria currently treated or worked with, indicated by participants in BMD
Table 4.12. Main other bacteria anticipated to be treated or worked with in three years from now, indicated by participants in BMD
Table 5.2. Main types of bacterial tests currently used, indicated by participants in BMD
Table 5.4. Main types of bacterial tests anticipated to be worked with in three years from now, indicated by participants in BMD
Table 6.2. Main sample types tested in bacterial diagnostics, indicated by participants in BMD
Table 7.2. Main bacterial molecular diagnostic techniques currently used, indicated by participants in BMD
Table 7.4. Main bacterial molecular diagnostic techniques anticipated to be used in three years from now, indicated by participants in BMD
Table 8.2. Main Gram negative bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.4. Main Gram negative bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 8.6. Main Gram positive bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.8. Main Gram positive bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 8.10. Main other bacteria currently tested for using molecular diagnostics, indicated by participants in BMD
Table 8.12. Main other bacteria anticipated to be tested for in three years from now, indicated by participants in BMD
Table 9.2. The number of different bacteria currently simultaneously tested for, indicated by participants in BMD
Table 9.3. The number of different bacteria anticipated to be simultaneously tested for in three years from now, indicated by participants in BMD
Table 10.2. The percentage of current bacterial molecular tests based on multiplex methods, indicated by participants in BMD
Table 10.3. The percentage of bacterial molecular tests anticipated to be based on multiplex methods in three years from now, indicated by participants in BMD
Table 11.2. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests over the last three years, indicated by participants in BMD
Table 11.3. The change (% increase or % decrease) in the use of bacterial molecular diagnostics tests anticipated over the next three years, indicated by participants in BMD
Table 12.2. Current main applications of bacterial molecular diagnostics, indicated by participants in BMD
Table 12.4. Main applications of bacterial molecular diagnostics anticipated in three years from now, indicated by participants in BMD
Table 13.2. Current main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents), indicated by participants in BMD
Table 13.4. Main suppliers of bacterial molecular diagnostics (e.g. diagnostics kits, reagents) anticipated in three years from now, indicated by participants in BMD
Table 14.2. The main advantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Table 14.4. The main disadvantages of bacterial molecular diagnostics compared to other (non-molecular) methods used in bacterial diagnostics, indicated by participants in BMD
Table 15.2. Main areas where end-users would like to see future improvements in bacterial molecular diagnostics, indicated by participants in BMD
Table 16.2. Techniques used in bacterial diagnostics that have been, or are being, replaced by bacterial molecular diagnostics methods, indicated by participants in BMD
Table 17.2. Percentage of end-users bacterial molecular diagnostics that are automated, indicated by participants in BMD
Table 18.2. Most tested Bacteria, in terms of the numbers of bacterial molecular diagnostic tests carried out, indicated by participants in BMD
Table 18.3. Cost per test (including associated replicates and controls) of your most tested bacterium using the associated molecular diagnostic, indicated by participants in BMD
Table 18.4. Percentage of end-users budget associated with the single bacterial molecular diagnostic tests indicated referred to, indicated by participants in BMD
Table 18.5. Preferred suppliers of the single bacterial molecular diagnostic tests previously referred to, indicated by participants in BMD
